
Vernon Sondak, MD, discusses CSCC risk classification, adjuvant cemiplimab in extremely high-risk disease, and the promise of neoadjuvant immunotherapy.

Vernon Sondak, MD, discusses CSCC risk classification, adjuvant cemiplimab in extremely high-risk disease, and the promise of neoadjuvant immunotherapy.

From hedgehog pathway mutations to next-generation sequencing, Vernon Sondak, MD, outlines a practical framework for complex BCC and CSCC workup.

Neil D. Gross, MD, FACS, discusses how anti–PD-1 therapy is changing treatment approaches in advanced CSCC.

Neil D. Gross, MD, FACS, discusses the heterogeneous nature of advanced CSCC.

Vernon Sondak, MD, discusses the importance of accurately distinguishing advanced cutaneous squamous cell carcinoma from basal cell carcinoma.